Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma
November 26, 2024
Citation: Fogliati, A., Zironda, A., Fiorentini, G. et al. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Ann Surg Oncol 31, 2632–2639 (2024). https://doi.org/10.1245/s10434-023-14875-5
Synopsis: This retrospective cohort study suggests that invasive Intraductal papillary mucinous cystic neoplasms (IPMN) have a better prognosis when compared to de novo pancreatic ductal adenocarcinoma, and their response to neoadjuvant chemotherapy appears non-inferior.